[ad_1]
Pfizer announced a profit increase for the third quarter Tuesday partly because of lower taxes, but also reduced its sales forecast due to the strength of the US dollar.
The pharmaceutical giant reported net income of $ 4,100 million, up 44.8% over the same period last year, after paying $ 661 million less after taxes in the United States.
Revenues increased 1% to $ 13.3 billion.
Pfizer has noted significant gains for a handful of key brands, including the anticoagulant Eliquis, the Ibrance breast cancer drug and the Prevnar vaccine.
These gains offset the impact of patent expiry of the drug against sexual dysfunction Viagra and some other drugs.
Pfizer has confirmed several key financial forecasts, but has brought the highest point in its annual revenue range to between $ 53,000 and $ 53,700 million from $ 53,000 to $ 55,000 million.
The company cited the lack of supplies of injectable Hospira products, as well as the strengthening of the dollar.
[ad_2]
Source link
